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Summary. Right ventricular (RV) dysfunction
contributes to poor clinical prognosis after pulmonary
embolism (PE). The present studies evaluate the effects
of angiotensin (1-7) (ANG (1-7)) upon RV function
during experimental PE in rats. Circulating ANG II
increased 8-fold 6 hr after PE (47±13 PE vs. 6±3 pg/mL,
control, p<0.05). ACE2 protein was uniformly localized
in the RV myocardium of control rats, but showed a
patchy distribution with some cells devoid of stain after
6 or 18 hr of PE. RV function decreased 18 hr after PE
compared with control treated animals (19±4 vs. 41±1
mmHg, respectively, p<0.05; 669±98 vs. 1354±77
mmHg/sec, respectively, p<0.05), while left ventricular
function (LV) was not significantly changed. Animals
treated with ANG (1-7) during PE showed improved RV
+dP/dt and peak systolic pressure development to values
not significantly different from control animals.
Protection of RV function by ANG (1-7) was associated
with improved arterial blood sO2, base excess and pH.
Supplemental delivery of ANG (1-7) reduced the
development of RV dysfunction, suggesting a novel
approach to protecting RV function in the setting of
acute experimental PE.
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Introduction
Pulmonary embolism (PE) is a major cardio-
pulmonary disease with an incidence of 1 per 1000
individuals, hospitalizing approximately 150,000
Americans per year (Stein et al., 2003). Mortality rate
exceeds 15% in the first 3 months (Piazza and
Goldhaber, 2006; Tapson, 2008; Torbicki et al., 2008),
but increases dramatically with the presence of right
ventricular (RV) dysfunction (Kreit, 2004; Schoepf et
al., 2004; Ten Wolde et al., 2004; Becattini and Agnelli,
2008; Watts et al., 2010). Our clinical studies show that
approximately forty percent of normotensive PE patients
have right ventricular (RV) dysfunction and ten percent
have persistent exercise intolerance (Kline et al., 2006;
Stevinson et al., 2007). These data suggest that it is
important to understand and regulate RV damage
following PE. Our rat studies show that moderate PE
produces a 3-fold increase pulmonary vascular resistance
(PVR) and injures the right ventricle (RV) by shear
forces, stretch, increased work and by a neutrophil-
mediated inflammatory response (Jones et al., 2003;
Zagorski et al., 2003, 2007, 2008, 2009; Watts et al.,
2006, 2008, 2009).
It has recently been discovered that several peptides
once thought to be breakdown products of the renin-
angiotensin system (RAS) possess biological activity,
thus prompting renewed interest in the regulation of
cardiovascular homeostasis via the balance of these
peptides (Ferreira and Raizada, 2008; Reudelhuber,
2005; Varagic et al., 2008). Of particular interest is the
counterbalance between the effects of angiotensin II
(ANGII) and angiotensin (1-7) (ANG (1-7)) (Diz, 2008;
Gallagher et al., 2008; Santos et al., 2008; Stewart et al.,
2008; Varagic et al., 2008). Acting via the AT1 receptor
(AT1R), ANG-II is prothrombotic, proinflammatory and
causes vasoconstriction, which might exacerbate RV
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injury from PE. Recent studies also indicate that ANG II
can decrease ACE2 expression, which may diminish
production of ANG (1-7) by this enzyme (Gallagher et
al., 2006, 2008; Koka et al., 2008; Zhang et al., 2009). In
contrast with ANG-II, ANG (1-7) acts via the Mas
receptor, has mild vasodilatory effects, promotes nitric
oxide synthesis and reduces ANG II signaling through
the AT1R (Reudelhuber, 2006; Stewart et al., 2008).
Activation of the RAS and the effects of ANG (1-7)
upon RV dysfunction in the setting of acute PE are, at
present, unknown. The present study examines ANG-II
formation and ACE 2 expression, following acute
experimental PE in rats and evaluates the effects ANG
(1-7) upon RV function during acute experimental PE. 
Materials and methods
Experiments were performed using male Sprague-
Dawley rats weighing between 350 and 400 g and were
conducted with the approval of the Institutional Animal
Care and Use committee of the Carolinas Medical
Center in accordance with the Guide for the Care and
Use of Laboratory Animals.
Pulmonary Embolism (PE) model and treatment groups
Microspheres (26±1 µm, 7525B, Thermo Scientific,
Freemont, CA) were sterilized with 70% ethanol,
washed with sterile 0.01% Tween 20, and resuspended in
0.01% sterile Tween 20 to produce a 10% suspension
(13 million beads/ml). Animals were anesthetized using
an intraperitoneal injection of xylazine (3 mg/kg) and
ketamine (70 mg/kg) and placed on a warming pad.
Microspheres (2.0 million beads/100 g body wt) were
injected via the right jugular vein to produce PE. Control
animals received all surgical treatments and the vehicle
for the microspheres (0.01% Tween 20, 0.15 ml/100 g
body wt). ANG (1-7) was injected intravenously 576
µg/kg), a dose that was previously described to be
effective in reducing myocardial injury from diabetic
hypertension (Benter et al., 2006, 2007, 2008).
Animals were euthanized 6 hours after treatment to
measure plasma ANG-II (n=6 control, 10 PE) and ACE-
2 immunohistochemistry (n=6) or after 18 hours to
measure in vivo hemodynamics (n=10-12/group),
cardiac function (n=12-18/group), ACE-2 immunohisto-
chemistry (n=6/group) and blood chemistry (n=10-
14/group).
Measurement of plasma ANG-II 
PE-50 tubing was inserted into the right carotid
artery and an aliquot of blood (5 ml) was removed into
EDTA containing tubes and centrifuged (3,000 rpm, 10
minutes, 4°C). The plasma was then aliquoted and stored
at -70°C until assay. Plasma samples (2 mL) were loaded
on to Strata Phenyl (55 µm, 70A, 500 mg/3mL) solid
phase columns (Phenomenex Inc., Torrence, CA) and
ANG-II was eluted with methanol (500 µL).
Angiotensin II concentration was determined using an
ELISA assay (SPI-Bio Product #589301, Cayman
Chemical, Ann Arbor, MI) according to the
manufacturers instructions. Standards were linear from 1
to 125 pg/mL (r2=0.9956). 
ACE-2 immunohistochemistry
Hearts were perfused briefly via the aorta to remove
blood from the coronary vasculature and ventricles. The
outflow tract of the RV was isolated, fixed in 10%
neutral buffered formalin, embedded in paraffin and cut
in cross-section. Sections were de-parafinized,
rehydrated and stained for ACE-2. The primary antibody
was rabbit polyclonal antibody (ACE2, H-175: sc-
20998, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), which was applied for 60 minutes (1:50 dilution).
The secondary antibody was rabbit/mouse biotinylated
link antibody (Dako, Carpentaria, CA) and sections were
processed with peroxidase-conjugated streptavidin and
diaminobenzidine/hydrogen peroxidase and were
counter-stained using 0.03% aqueous light green stain
(Polysciences, Warrington, PA).
Hemodynamics, in vitro heart function, and blood
chemistry
Animals were anesthetized with xylazine (3 mg/kg)
and ketamine (70 mg/kg) and placed on a warming pad
filled with re-circulating water warmed to 105°F
(Graymar solid-state T-pump; Orchard Park, NY) for the
study of in vivo hemodynamics and blood chemistry. A
2-French Millar Mikro-Tip catheter transducer (SPR-
249-A Millar Instruments, Houston, TX) was placed in
the left carotid artery to monitor systemic pressures. A 2-
French bent Millar catheter (SPR-513) was inserted into
1288
Angiotensin 1-7 in pulmonary embolism
Fig. 1. Changes in circulating plasma levels of ANG-II seen with PE.
Values are mean ± s.e., n=6-10, stars indicate significantly different
values.
the right ventricle via the right jugular vein and
intermittently advanced into the RV to monitor
intraventricular pressures. The transducers were
connected to a Transducer Balance Box, a UM 100A
coupling box and an MP100 data acquisition unit, which
was connected to a personal computer. Pressures were
recorded using AcKnowledge software (BIOPAC
Systems, Inc., Santa Barbara, CA). The arterial catheter
was removed and PE-50 tubing was inserted to sample
arterial blood (1 mL) for blood chemistry (i-STAT,
MN300, Abbott Point of Care, Princeton, NJ) using
CG4+ cartridges.
For the study of intrinsic cardiac function, hearts
were removed from anesthetized rats via midline
thoracotomy and placed in ice-cold saline. The aorta was
perfused at 60 mm Hg in a non-recirculating,
temperature-controlled (37°C) system. The perfusion
solution, Krebs-Henseleit bicarbonate buffer, consisted
of (in mmol/L): 118 NaCl, 4.7 KCl, 21 NaHCO3, 1.25CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 11 glucose and .05
octanoate, which was gassed with 95% O2/ 5% CO2.
Hearts were perfused to assess intrinsic function of right
ventricle (RV) and left ventricle (LV) using two
independent balloons, as previously described (Watts et
al., 2006). Briefly, each latex balloon was tested to
ensure that balloon volume was well-matched for
ventricular volumes. Balloons were filled with saline and
connected by PE tubing to Statham transducers (P23,
Gould Electronics, Millersville, MD) via PE-60 tubing.
Pressures were recorded using AcKnowledge software,
as described above. Initial volumes of the RV and the LV
balloons established 0 mm Hg end diastolic pressure
(EDP). Hearts were then paced (300 beats/min, 5-ms
duration, 5 volts) using a Grass SD9 stimulator (Astro-
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Fig. 2. Immunohistochemical localization of ACE2 protein in control hearts. A. Longitudinal view showing positive stain in the myocardium (Myo) and
not in the blood vessel tissue (BV). B. Negative control. C. Cross-section view of the myocardium showing positive stain in the cytoplasm (white arrows)
and nuclei (black arrow). D. Negative control. Bars: A, B, 40 µm; C, D, 20 µm.
Med, West Warwick, RI) and electrodes attached to the
aortic cannula and the apex of the heart to allow direct
comparison of pressure data among treatment groups.
Heart perfusion was continued for each heart until stable
heart function was obtained (10-15 min) before taking
data for the heart. Heart function end points included
peak systolic pressure (PSP) and maximum rate of
pressure development (+dP/dt).
Statistical analyses
Values are presented as mean ± SE. Comparisons of
three or more independent groups were made by
ANOVA with Tukey’s post-hoc testing with uneven
sample sizes or Student-Newman-Keuls testing with
equal sample sizes. Comparisons of two independent
groups were made using Student’s t-test. Significance
was determined as p<0.05 using two-tailed testing. 
Results
Plasma ANG II 
Plasma ANG II levels increased 8-fold (Fig. 1)
following 6 hours of PE, indicating that the rennin-
angiotensin system is activated by the cardiovascular
stress of PE.
ACE-2 immunohistochemistry 
ACE-2 protein was localized to the right ventricular
myocardium and myocardial cell nucleus, but not the
vascular tissue, in control animals (Fig. 2A,C). There
was a uniform distribution of stain in the myocardium in
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Fig. 3. Immunohistochemical localization of ACE2 protein in right ventricular tissue six hours after PE (A and C) and 18 hours after PE (B and D).
There is patchy distribution of stain in some myocardial cells (black arrows) with regions that are unstained (white arrows). Bars: A, B, 40 µm; C, D, 20
µm.
these animals. Stain was not observed when the primary
antibody was omitted from the reaction (Fig. 2B,D). In
contrast with the homogeneous stain observed in control
animals, ACE2 distribution was patchy with some cells
devoid of stain (white arrows) interspaced among cells
with stain (black arrows) in the right ventricular
myocardium of hearts examined 6 hours (Fig. 3A,C) or
18 hours (Fig. 3B,D) after PE. 
Heart function
Hemodynamic measurements, made in vivo,
indicated that experimental PE caused moderate
pulmonary hypertension as indicated by increased right
ventricular peak systolic pressure (47±2 mmHg PE, vs.
28±1 Control, p<0.05), and mild systemic hypotension
with decreased mean arterial pressure (77±5 PE, vs.
123±6 Control, p<0.05, n=10-12/group) 18 hours after
treatment. 
Intrinsic right ventricular function, observed in
isolated, perfused hearts, decreased following 18 hours
of PE as evidenced by a 70% decrease in +dP/dt and a
50% decrease in systolic pressure compared with control
animals (Fig. 4A,B). Treatment of rats with ANG (1-7)
during PE resulted in a significant improvement in both
+dP/dt and peak systolic pressure of the RV (Figure
4A,B). These values were not significantly different
from those observed in control animals. In contrast with
the RV, LV function was not significantly changed by PE
or by treatment with ANG (1-7) (Fig. 4C,D).
Differences observed in right ventricular function
among treatment groups were not due to heart rate (set at
300 bpm), coronary flow or balloon volume, which were
not significantly different (p>0.05). Therefore, changes
in +dP/dt and peak systolic pressure reflects differences
in intrinsic contractile function among treatment groups.
Arterial blood chemistry
Pulmonary embolism also resulted in significant
alterations in arterial blood chemistry with reduced sO2,
negative base excess and acidosis (Fig. 5). Treatment
with ANG (1-7) ameliorated these changes (Fig. 5),
suggesting that improved cardiac function, observed in
vitro, was associated with improved arterial blood
chemistry in vivo. 
Discussion
The present studies show that acute, experimental
PE increased circulating ANG II and decreased right
ventricular myocardial expression of ACE2 protein. In
addition, right ventricular contractile function was
depressed (decreased +dP/dt and peak systolic pressure),
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Fig. 4. Intrinsic cardiac
contractile function determined
in perfused hearts isolated 18
hours after treatment in vivo
with control, pulmonary
embolism (PE) or PE with
ANG (1-7). A. RV +dP/dt. B.
RV Peak systolic pressure. C.
LV +dP/dt. D. LV Peak systolic
pressure. Values are mean ±
s.e., n=12-18/group. 
*: indicates a value
significantly different from
control and PE + ANG (1-7).
while LV function was unchanged following PE. The
addition of ANG (1-7) during PE, improved both +dP/dt
and peak systolic pressure in the right ventricle and
improved arterial blood gas levels. Thus, the present
studies suggest that supplementation with ANG (1-7)
may be beneficial in the setting of acute PE.
ANG-II acts primarily upon AT1 receptors (AT1R)
causing Ca++- dependent smooth muscle contraction and
pulmonary precapillary vasoconstriction, salt and water
retention, inflammation, thrombosis, fibrosis, increased
cyclooxygenase-2 expression and increased oxidative
stress (Suzuki et al., 2003; Diz, 2008). ANG (1-7)
opposes many of the actions of ANG-II by decreasing
ANG-II signaling through AT1R (Diz, 2008; Stewart et
al., 2008), decreasing oxidative stress (Benter et al.,
2006, 2007, 2008), activating beneficial levels of NO
formation and Akt survival pathway (Giani et al., 2007;
Sampaio et al., 2007), and reducing COX-2 expression,
thereby lowering formation of constrictive
prostaglandins and increasing formation of prostacyclin
(Clark et al., 2003; Dartevelle et al., 2004; Bresser et al.,
2006; Menon et al., 2007; Diz, 2008) Tipping the
balance of ANG-II and ANG (1-7) towards the latter
might therefore mitigate RV damage from PE. Recent
clinical trials indicate that ANG (1-7) is well tolerated in
humans and it appears to have antiproliferative
capabilities and reduces cancer growth in a phase I trial
(Petty et al., 2009), and beneficial effects in human
diabetic nephropathy (Ferrario and Varagic, 2010) and
chronic hypertension (Ferrario et al., 2010).
We found a significant elevation in circulating ANG-
II and decreased ACE2 protein expression following
experimental PE. Thus, the balance of these two factors
is in favor of ANG II. Several factors may reduce the
expression of ACE2 during PE. Increased input by ANG
II to AT1R decreased ACE2 protein expression and ANG(1-7) formation in several systems (Gallagher et al.,
2006, 2008; Koka et al., 2008; Zhang et al., 2009). We
have also previously shown that acute PE induces
expression of HIF-1α in the RV of rats (Zagorski et al.,
2008). Increased HIV-1α upregulates ACE activity and
ANG II formation, while decreasing ACE2 protein
expression in hypoxic pulmonary artery smooth muscle
cells (Zhang et al., 2009). Thus, there are at least two
pathways reducing ACE2 protein expression, thereby
tipping the balance toward ANG-II. 
Administration of exogenous ANG (1-7) improved
+dP/dt and peak generated systolic pressure in the
setting of acute experimental PE. It has previously been
reported that ANG (1-7) decreases chronic hypertension,
but has little effect on systemic pressure in normal
animals (Chappell et al., 1998). Pulmonary vasodilation
would be beneficial during PE, but excessive systemic
vasodilation could be detrimental, especially if right
ventricular preload were reduced out of proportion to
pulmonary vascular relaxation. Increased ANG (1-7)
production via fusion protein in rats caused increased
cardiac output with decreased total peripheral resistance
and decreased vascular resistance to the lung, and other
organs, suggesting a physiological role in tonic control
of regional blood flow (Sampaio et al., 2003; Botelho-
Santos et al., 2007). ANG (1-7) has also been shown to
counteract the ANG-II mediated vasoconstriction,
increased vascular permeability and hydrostatic edema
formation in acute respiratory distress syndromes
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Fig. 5. Arterial blood hemoglobin saturation sO2 (A), base excess (B)
and pH (C) observed 18 hours after control treatment, PE, or PE + ANG
(1-7). Values are mean ± s.e., n = 10-14/group. *: indicates a value
significantly different from control and PE + ANG (1-7).
(ARDS) (Imai et al., 2008). ANG (1-7) also decreases
thrombus formation (Kucharewicz et al., 2002). Thus,
ANG (1-7) appears to have positive effects upon
multiple homeostatic pathways that should be beneficial
in the setting of PE. The present studies show that
supplemental delivery of ANG (1-7) reduces the
development of RV dysfunction and enhances blood gas
exchange.
The present studies show that plasma ANG II levels
increase markedly during experimental PE and ACE-2
expression is reduced, suggesting an imbalance favoring
ANG II over ANG (1-7) during PE. The supplemental
delivery of ANG (1-7) reduces the development of RV
dysfunction, suggesting a novel approach to protecting
RV function in the setting of acute PE. 
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